Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

Research output: Contribution to journalJournal articleResearchpeer-review


  • Fulltext

    Final published version, 6.97 MB, PDF document

  • Emdal, Kristina Bennet
  • Nicolàs Palacio-Escat
  • Caroline Wigerup
  • Akihiro Eguchi
  • Helén Nilsson
  • Dorte B. Bekker-Jensen
  • Lars Rönnstrand
  • Julhash U Kazi
  • Alexandre Puissant
  • Raphaël Itzykson
  • Julio Saez-Rodriguez
  • Kristina Masson
  • Peter Blume-Jensen
  • Olsen, Jesper Velgaard

Acute myeloid leukemia (AML) is a heterogeneous disease with variable patient responses to therapy. Selinexor, an inhibitor of nuclear export, has shown promising clinical activity for AML. To identify the molecular context for monotherapy sensitivity as well as rational drug combinations, we profile selinexor signaling responses using phosphoproteomics in primary AML patient samples and cell lines. Functional phosphosite scoring reveals that p53 function is required for selinexor sensitivity consistent with enhanced efficacy of selinexor in combination with the MDM2 inhibitor nutlin-3a. Moreover, combining selinexor with the AKT inhibitor MK-2206 overcomes dysregulated AKT-FOXO3 signaling in resistant cells, resulting in synergistic anti-proliferative effects. Using high-throughput spatial proteomics to profile subcellular compartments, we measure global proteome and phospho-proteome dynamics, providing direct evidence of nuclear translocation of FOXO3 upon combination treatment. Our data demonstrate the potential of phosphoproteomics and functional phosphorylation site scoring to successfully pinpoint key targetable signaling hubs for rational drug combinations.

Original languageEnglish
Article number111177
JournalCell Reports
Issue number6
Number of pages25
Publication statusPublished - 2022

Bibliographical note

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

    Research areas

  • Apoptosis, Cell Line, Tumor, Humans, Hydrazines, Leukemia, Myeloid, Acute/drug therapy, Proteome/metabolism, Proto-Oncogene Proteins c-akt/metabolism, Triazoles, Tumor Suppressor Protein p53/metabolism

Number of downloads are based on statistics from Google Scholar and

No data available

ID: 316560905